An important result shown by the Oxford vaccine against Corona!

Press reports revealed that data from early experiments showed that the “Corona” virus vaccine developed by the British University of “Oxford” produces a strong immune response in the elderly, who are among the groups most at risk for develop complications from the epidemic.

According to data published in the medical journal “Lancet”, the results of the first and second stages of the trials indicate that the elderly can develop strong immunity.

This comes a day after the “Pfizer” company announced the effectiveness of the “Corona” vaccine, which it developed in partnership with the “Biontech” company, in 94% among people over 65 years of age.

The American company “Moderna” has also announced that the effectiveness of its vaccine is close to 95%.

Approximately 560 healthy adult volunteers participated in the second phase of the Oxford trials, where they were given two doses of the vaccine that was being developed, while others received a placebo.

“Sky News” cited the report that no harmful health problems were reported during the trials.

The University of Oxford says that in most cases, the elderly tend not to respond to vaccines and develop the necessary immunity just like younger adults, since the antibodies that are stimulated by the vaccine often show a lower protection capacity.

“The elderly are a priority group for the ‘Covid-19’ vaccine, because they have a higher risk of developing serious disease, but we know that they have a weak response to vaccines,” said an Oxford Vaccine Group researcher and consultant physician, Mahshi Ramasamy.

He added: “We are pleased to see that not only were the elderly able to tolerate our vaccine, but it also stimulated immune responses similar to those seen in younger volunteers. The next step will be to see if this translates into protection against the disease itself.”

Trials of the third phase of the “Oxford” vaccine, which will determine the effectiveness of the vaccine, are still ongoing, and results are expected in the coming weeks.

Studies indicate that the Oxford vaccine will not need to be stored at lower temperatures, as is the case with the Pfizer and Moderna vaccines.

The head of the Oxford vaccine testing team, Professor Andrew Pollard, said: “There is no competition between different vaccines, because we need several vaccines to be successful, since we have many people who need protection around the world.”